Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin
Journal of Cardiovascular Development and Disease · 11.06.2026 · 13 (6) · 259
DOI: 10.3390/jcdd13060259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 11.06.2026. Verfasst von Hussein Abdul Nabi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
AF in the setting of cardiac amyloidosis is associated with a high risk of TEs, irrespective of CHA2DS2-VASc score. While warfarin has been the traditional anticoagulant, DOACs offer a promising alternative, but their safety in this population remains underexplored. This study aimed to evaluate the prevalence of thromboembolic events (TEs), including stroke and transient ischemic attack (TIA), and major bleeding events in patients with cardiac amyloidosis (CA) and atrial fibrillation (AF) treated with either warfarin or direct oral anticoagulants (DOACs). Additionally, we aimed to explore whether DOACs are at least as effective as warfarin in protecting against TEs in this population.
Methods
This retrospective cohort study analyzed 422 patients with confirmed CA and AF from Mayo Clinic, with a median follow-up of 4.3 years. Data on anticoagulation therapy, baseline characteristics, and outcomes (TEs and bleeding) were collected. Statistical analyses included chi-square tests, t-tests, and Cox regression to assess the relationship between anticoagulation and TE.
Results
Among 422 patients, 21 experienced a TE. The annual event rate was 0.83% for warfarin and 0.67% for DOACs, with no significant difference (HR 0.66, CI 0.22–2.01, p = 0.5). Patients with anticoagulation interruptions > 5 days had increased TE risk (HR 3.19, CI 0.97–10.5, p = 0.056). The bleeding rate was 9.9% over 4.3 years (2.33% per year), with no significant differences between anticoagulants.
Conclusions
Both warfarin and DOACs have similar, low risks of TEs in CA and AF patients. However, anticoagulation interruptions were associated with increased TE risk, emphasizing the challenges in managing anticoagulation in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
ORCID-Profile: Hussein Abdul Nabi, Luke Dreher, Michael Liu, Suganya A Karikalan, Hicham Z El Masry
Zitieren
APA
Abdul Nabi, H., Dreher, L., Liu, M., Al Osta, S., Karikalan, S. A., Habib, E., & El Masry, H. Z. (2026). Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin. Journal of Cardiovascular Development and Disease, 13(6), 259. https://doi.org/10.3390/jcdd13060259
Vancouver
Abdul Nabi H, Dreher L, Liu M, Al Osta S, Karikalan SA, Habib E, et al. Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin. Journal of Cardiovascular Development and Disease. 2026;13(6):259. doi:10.3390/jcdd13060259
BibTeX
@article{AbdulNabi2026,
author = {Abdul Nabi, Hussein and Dreher, Luke and Liu, Michael and Al Osta, Soad and Karikalan, Suganya A and Habib, Eiad and El Masry, Hicham Z},
title = {Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {6},
pages = {259},
doi = {10.3390/jcdd13060259}
}
EUVIMED